MedTrace Logo

Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate

NCT03698721 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 365

Last updated 2018-10-09

No results posted yet for this study

Summary

Different clinical conditions can require urinary bladder augmentation or replacement. Tissue engineered bladder has been clinically evaluated but is not recommended due to diverse side effects. Thus, there is a real interest for the development of regenerative approach with innovative scaffolds and cell transplantation.

The investigators propose the use of urothelial cells obtained by Trans-Urethral Resection of Prostate or bladder (TURP) to obtain a tissue engineered urothelium in association with different scaffolds.

Conditions

  • Spina Bifida
  • Urothelial Neoplasm
  • Bladder, Neurogenic
  • Bladder Exstrophy
  • Hypospadias

Interventions

PROCEDURE

Transurethral Resection of Prostate

Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-31
Primary Completion
2024-10-31
Completion
2026-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698721 on ClinicalTrials.gov